[
  {
    "ts": null,
    "headline": "Jim Cramer on Amgen: “Company Announced Some Very Promising Heart Attack Prevention Results”",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer offered insights on. Cramer discussed the stock’s rally and the company’s cholesterol drug phase 3 trial. He stated: “In the last few weeks, the long-dormant healthcare sectors finally started to show a little life. It’s so inexpensive, it’s crazy. Take Amgen, the big biotech company […]",
    "url": "https://finnhub.io/api/news?id=524e336072a64b0b64acc803c868131727ed1bdf2d3ab79340d97cba65edc34d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762889678,
      "headline": "Jim Cramer on Amgen: “Company Announced Some Very Promising Heart Attack Prevention Results”",
      "id": 137449929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer offered insights on. Cramer discussed the stock’s rally and the company’s cholesterol drug phase 3 trial. He stated: “In the last few weeks, the long-dormant healthcare sectors finally started to show a little life. It’s so inexpensive, it’s crazy. Take Amgen, the big biotech company […]",
      "url": "https://finnhub.io/api/news?id=524e336072a64b0b64acc803c868131727ed1bdf2d3ab79340d97cba65edc34d"
    }
  },
  {
    "ts": null,
    "headline": "Executive Calls DEI Rollbacks 'Shortsighted' for Business",
    "summary": "Ellen Kullman, board director for Amgen, Carbon, and Goldman Sachs weighs in on the delicate balance between stakeholders and shareholders when creating company policies that impact employee engagement.",
    "url": "https://finnhub.io/api/news?id=3498cd165842230c08bc13cc08e8b6eee01a5a7c21f5ceb09fdceb68c87a67ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762884720,
      "headline": "Executive Calls DEI Rollbacks 'Shortsighted' for Business",
      "id": 137449912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Ellen Kullman, board director for Amgen, Carbon, and Goldman Sachs weighs in on the delicate balance between stakeholders and shareholders when creating company policies that impact employee engagement.",
      "url": "https://finnhub.io/api/news?id=3498cd165842230c08bc13cc08e8b6eee01a5a7c21f5ceb09fdceb68c87a67ef"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=ed16c1e52c183e5bb16253a13bcfa3796a19193a2d324deeae70ea79e7999f6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762869602,
      "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 137448877,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=ed16c1e52c183e5bb16253a13bcfa3796a19193a2d324deeae70ea79e7999f6a"
    }
  },
  {
    "ts": null,
    "headline": "Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine",
    "summary": "Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar TherapeuticsLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine. “",
    "url": "https://finnhub.io/api/news?id=6f3a05d00caefe1290e8db65741f1f723875c884a86310e4540cda76dece94e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762866000,
      "headline": "Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine",
      "id": 137448878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar TherapeuticsLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine. “",
      "url": "https://finnhub.io/api/news?id=6f3a05d00caefe1290e8db65741f1f723875c884a86310e4540cda76dece94e4"
    }
  },
  {
    "ts": null,
    "headline": "Obesity Drugs Are About to Go Mass-Market",
    "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
    "url": "https://finnhub.io/api/news?id=229a408931ff92dcb9dcee7ea1027d0413a16f2ffee778ccc7af5a424f69a726",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762857000,
      "headline": "Obesity Drugs Are About to Go Mass-Market",
      "id": 137448682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
      "url": "https://finnhub.io/api/news?id=229a408931ff92dcb9dcee7ea1027d0413a16f2ffee778ccc7af5a424f69a726"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Amgen’s Q3 Earnings Call",
    "summary": "Amgen’s third quarter results were well received by the market, reflecting robust volume-driven growth across its diversified portfolio. Management credited rising demand for key medicines—including Repatha, EVENITY, TEZSPIRE, and its rare disease and biosimilar portfolios—as major contributors to the company’s 12% year-over-year revenue increase. CEO Robert Bradway highlighted, “Volume growth reflects the strength of our portfolio and the value our medicines provide to patients and prescribers.",
    "url": "https://finnhub.io/api/news?id=117d30721e9f7f3330fe4b43e1c48d7c13e1bf4cf80995cb37a92d227d06c8a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762839257,
      "headline": "The Top 5 Analyst Questions From Amgen’s Q3 Earnings Call",
      "id": 137448880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen’s third quarter results were well received by the market, reflecting robust volume-driven growth across its diversified portfolio. Management credited rising demand for key medicines—including Repatha, EVENITY, TEZSPIRE, and its rare disease and biosimilar portfolios—as major contributors to the company’s 12% year-over-year revenue increase. CEO Robert Bradway highlighted, “Volume growth reflects the strength of our portfolio and the value our medicines provide to patients and prescribers.",
      "url": "https://finnhub.io/api/news?id=117d30721e9f7f3330fe4b43e1c48d7c13e1bf4cf80995cb37a92d227d06c8a8"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From GoodRx’s Q3 Earnings Call",
    "summary": "GoodRx’s third quarter results were met with a moderate positive market response, as the company’s revenue modestly exceeded Wall Street expectations despite being flat year-over-year. Management highlighted a mix of strategic wins, such as expanded partnerships with pharmaceutical manufacturers and new pharmacy integrations, as key drivers. CEO Wendy Barnes cited the launch of direct-to-consumer pricing programs with major brands like Novo Nordisk and Amgen, as well as the rollout of the RxSmar",
    "url": "https://finnhub.io/api/news?id=5c8bdc0927dc51650262103a4abc16b4f3df91493aa79f03a5d29701d94a3d42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762839227,
      "headline": "5 Revealing Analyst Questions From GoodRx’s Q3 Earnings Call",
      "id": 137448881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "GoodRx’s third quarter results were met with a moderate positive market response, as the company’s revenue modestly exceeded Wall Street expectations despite being flat year-over-year. Management highlighted a mix of strategic wins, such as expanded partnerships with pharmaceutical manufacturers and new pharmacy integrations, as key drivers. CEO Wendy Barnes cited the launch of direct-to-consumer pricing programs with major brands like Novo Nordisk and Amgen, as well as the rollout of the RxSmar",
      "url": "https://finnhub.io/api/news?id=5c8bdc0927dc51650262103a4abc16b4f3df91493aa79f03a5d29701d94a3d42"
    }
  }
]